SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis
Resumen:
Background: Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer- BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine. Patients and methods: We performed a retrospective study on AIH patients with COVID-19. The outcomes of AIH patients who had acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection after at least one dose of COVID-19 vaccine were compared to unvaccinated patients with AIH. COVID-19 outcome was classified according to clinical state during the disease course as: (i) no hospitalization, (ii) hospitalization without oxygen supplementation, (iii) hospitalization with oxygen supplementation by nasal cannula or mask, (iv) intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v) ICU admission with invasive mechanical ventilation or (vi) death, and data was analyzed using ordinal logistic regression. Results: We included 413 (258 unvaccinated and 155 vaccinated) patients (81%, female) with a median age of 52 (range: 17-85) years at COVID-19 diagnosis. The rates of hospitalization were (36.4% vs. 14.2%), need for any supplemental oxygen (29.5% vs. 9%) and mortality (7% vs. 0.6%) in unvaccinated and vaccinated AIH patients with COVID-19. Having received at least one dose of SARS-CoV-2 vaccine was associated with a significantly lower risk of worse COVID-19 severity, after adjusting for age, sex, comorbidities and presence of cirrhosis (adjusted odds ratio [aOR] 0.18, 95% confidence interval [CI], 0.10-0.31). Overall, vaccination against SARS-CoV-2 was associated with a significantly lower risk of mortality from COVID-19 (aOR 0.20, 95% CI 0.11-0.35). Conclusions: SARS-CoV-2 vaccination significantly reduced the risk of COVID-19 severity and mortality in patients with AIH.
| 2022 | |
|
Autoimmunity Breakthrough infection Immunosuppression Liver failure Vaccine COVID-19 VACUNAS CONTRA LA COVID-19 AUTOINMUNIDAD RIESGO A LA SALUD ADULTOS ADOLESCENTE PERSONA DE MEDIANA EDAD ANCIANO HEPATITIS AUTOINMUNE VACUNA BNT162 PRUEBA DE COVID-19 PREVENCIÓN DE ENFERMEDADES HUMANOS ESTUDIOS RETROSPECTIVOS SARS-CoV-2 EPIDEMIOLOGÍA VACUNACIÓN |
|
| Inglés | |
| Universidad de la República | |
| COLIBRI | |
| https://hdl.handle.net/20.500.12008/54650 | |
| Acceso abierto | |
| Licencia Creative Commons Atribución (CC - By 4.0) |
| _version_ | 1872865103255175168 |
|---|---|
| author | Efe, Cumali |
| author2 | Taşçılar, Koray Gerussi, Alessio Bolis, Francesca Lammert, Craig Ebik, Berat Stättermayer, Albert F. Cengiz, Mustafa Gökçe, Dilara Turan Hernández, Nelia |
| author2_role | author author author author author author author author author |
| author_facet | Efe, Cumali Taşçılar, Koray Gerussi, Alessio Bolis, Francesca Lammert, Craig Ebik, Berat Stättermayer, Albert F. Cengiz, Mustafa Gökçe, Dilara Turan Hernández, Nelia |
| author_role | author |
| bitstream.checksum.fl_str_mv | 6429389a7df7277b72b7924fdc7d47a9 a0ebbeafb9d2ec7cbb19d7137ebc392c 0e79e635ad5d883764003e78793ad1de e7132498e7c1fe99f7096667baa99b25 7423378789254038f4f1a94094dff740 |
| bitstream.checksumAlgorithm.fl_str_mv | MD5 MD5 MD5 MD5 MD5 |
| bitstream.url.fl_str_mv | http://localhost:8080/xmlui/bitstream/20.500.12008/54650/5/license.txt http://localhost:8080/xmlui/bitstream/20.500.12008/54650/2/license_url http://localhost:8080/xmlui/bitstream/20.500.12008/54650/3/license_text http://localhost:8080/xmlui/bitstream/20.500.12008/54650/4/license_rdf http://localhost:8080/xmlui/bitstream/20.500.12008/54650/1/SARS+CoV2+vaccination+and+risk+of+severe+COVID19+outcomes.pdf |
| collection | COLIBRI |
| dc.contributor.filiacion.none.fl_str_mv | Efe Cumali, Harran University Hospital (Turquía). Department of Gastroenterology Taşçılar Koray, Friedrich-Alexander University of Erlangen–Nuremberg (Alemania). Department of Medicine 3-Rheumatology and Immunology Gerussi Alessio, San Gerardo Hospital (Italia). European Reference Network on Hepatological Diseases Bolis Francesca, Università degli Studi di Milano-Bicocca (Italia). Department of Medicine and Surgery. Division of Gastroenterology and Center for Autoimmune Liver Diseases Lammert Craig, Indiana University School of Medicine (E.E.U.U.). Department of Medicine Ebik Berat, Gazi Yaşargil Education and Research Hospital (Turquía). Department of Gastroenterology Stättermayer Albert F., Medical University of Vienna (Austria). Department of Internal Medicine III, Division of Gastroenterology and Hepatology Cengiz Mustafa, Gülhane Training and Research Hospital (Turquía). Department of Gastroenterology Gökçe Dilara Turan, Ankara City Hospital (Turquía). Department of Gastroenterology Hernández Nelia, Universidad de la República (Uruguay). Facultad de Medicina. Unidad de Gastroenterología y Hepatología |
| dc.creator.none.fl_str_mv | Efe, Cumali Taşçılar, Koray Gerussi, Alessio Bolis, Francesca Lammert, Craig Ebik, Berat Stättermayer, Albert F. Cengiz, Mustafa Gökçe, Dilara Turan Hernández, Nelia |
| dc.date.accessioned.none.fl_str_mv | 2026-04-28T17:28:34Z |
| dc.date.available.none.fl_str_mv | 2026-04-28T17:28:34Z |
| dc.date.issued.none.fl_str_mv | 2022 |
| dc.description.abstract.none.fl_txt_mv | Background: Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer- BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine. Patients and methods: We performed a retrospective study on AIH patients with COVID-19. The outcomes of AIH patients who had acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection after at least one dose of COVID-19 vaccine were compared to unvaccinated patients with AIH. COVID-19 outcome was classified according to clinical state during the disease course as: (i) no hospitalization, (ii) hospitalization without oxygen supplementation, (iii) hospitalization with oxygen supplementation by nasal cannula or mask, (iv) intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v) ICU admission with invasive mechanical ventilation or (vi) death, and data was analyzed using ordinal logistic regression. Results: We included 413 (258 unvaccinated and 155 vaccinated) patients (81%, female) with a median age of 52 (range: 17-85) years at COVID-19 diagnosis. The rates of hospitalization were (36.4% vs. 14.2%), need for any supplemental oxygen (29.5% vs. 9%) and mortality (7% vs. 0.6%) in unvaccinated and vaccinated AIH patients with COVID-19. Having received at least one dose of SARS-CoV-2 vaccine was associated with a significantly lower risk of worse COVID-19 severity, after adjusting for age, sex, comorbidities and presence of cirrhosis (adjusted odds ratio [aOR] 0.18, 95% confidence interval [CI], 0.10-0.31). Overall, vaccination against SARS-CoV-2 was associated with a significantly lower risk of mortality from COVID-19 (aOR 0.20, 95% CI 0.11-0.35). Conclusions: SARS-CoV-2 vaccination significantly reduced the risk of COVID-19 severity and mortality in patients with AIH. |
| dc.description.es.fl_txt_mv | Cumali Efe a,∗,1, Koray Taşçılar b,1, Alessio Gerussi c,d, Francesca Bolis c, Craig Lammert e, Berat Ebik f, Albert Friedrich Stättermayer g, Mustafa Cengiz h, Dilara Turan Gökçe i, Laura Cristoferi c,d, Mirta Peralta j,k, Hatef Massoumi l, Pedro Montes m, Eira Cerda n, Cristina Rigamonti o,p, Suna Yapalı q, Gupse Adali r, Ali Rıza Çalışkan s, Yasemin Balaban t, Fatih Eren u, Tuğçe Eşkazan v, Sezgin Barutçu w, Ellina Lytvyak x, Godolfino Miranda Zazueta y, Meral Akdogan Kayhan h, Alexandra Heurgue-Berlot z, Eleonora De Martin aa, Ahmet Yavuz ab, Murat Bıyık ab, Graciela Castro Narro y, Serkan Duman ac, Nelia Hernandez ad, Nikolaos K Gatselis ae,af, Jonathan Aguirre ag, Ramazan Idilman ac, Marcelo Silva k,ah, Manuel Mendizabal k,ah, Kadri Atay ai, Fatih Güzelbulut aj, Renumathy Dhanasekaran ak, Aldo J Montano-Loza x, George N Dalekos ae,af,2, Ezequiel Ridruejo k,ah,al,2, Pietro Invernizzi c,d,2, Staffan Wahlin am,2 aDepartment of Gastroenterology, Harran University Hospital, Şanlıurfa, Turkey bDepartment of Medicine 3-Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany cDivision of Gastroenterology and Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy dEuropean Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital, Monza, Italy eDepartment of Medicine Indiana, University School of Medicine, Indianapolis, IN, USA fDepartment of Gastroenterology, Gazi Yaşargil Education and Research Hospital, Diyarbakir, Turkey gDivision of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria hDepartment of Gastroenterology, Gülhane Training and Research Hospital, Ankara, Turkey iDepartment of Gastroenterology, Ankara City Hospital, Ankara, Turkey jHepatology Section, Hospital Francisco J Muñiz, Ciudad Autónoma de Buenos Aires, Argentina kLatin American Liver Research Educational and Awareness Network (LALREAN), Pilar, Argentina lDepartment of Medicine, Montefiore Medical Center, Bronx, NY, USA mGastroenterology and Hepatology Unit, Hospital Nacional Daniel A. Carrión, Callao, Peru nHepatology Unit, Hospital Militar Central de México, Ciudad de México, Mexico oDepartment of Translational Medicine, Università del Piemonte Orientale UPO, Novara, Italy pDivision of Internal Medicine, “AOU Maggiore della Carità”, Novara, Italy qDepartment of Gastroenterology, Acıbadem University School of Medicine, İstanbul, Turkey rDepartment of Gastroenterology, Umraniye Education and Research Hospital, Istanbul, Turkey sDepartment of Gastroenterology, Adıyaman University, Adıyaman, Turkey tDepartment of Gastroenterology, Faculty of Medicine, Hacettepe University, Ankara, Turkey uDepartment of Gastroenterology, Medical Faculty, Uludag University, Bursa, Turkey vDepartment of Gastroenterology, Cerrahpaşa School of Medicine, İstanbul, Turkey wDepartment of Gastroenterology, University of Gaziantep Medical Faculty, Gaziantep, Turkey xUniversity of Alberta Division of Gastroenterology and Liver Unit, Edmonton, AB, Canada yGastroenterology Unit, Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, Ciudad de México, Mexico zDepartment of Hepato-Gastroenterology, CHU Reims, Reims, France aaCentre Hepato-Biliaire, Hôpital Paul-Brousse, FHU Hepatinov, INSERM Unit UMR 1193, Univ Paris-Saclay, France abDivision of Gastroenterology, Necmettin Erbakan University, Meram School of Medicine, Konya, Turkey acDepartment of Gastroenterology, Ankara University Medical Faculty, Ankara, Turkey adGastroenterology and Hepatology Unit, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay aeDepartment of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, Greece afEuropean Reference Network on Hepatological Diseases (ERN RARE-LIVER), General University Hospital of Larissa, Larissa, Greece agHepatology Unit, Hospital Ángeles Pedregal, Ciudad de México, Mexico ahHepatology and Liver Transplant Unit, Hospital Universitario Austral, Pilar, Argentina aiDepartment of Gastroenterology, Mardin State Hospital, Mardin, Turkey ajDepartment of Gastroenterology, Haydarpaşa Numune Education and Research Hospital, İstanbul, Turkey akDivision of Gastroenterology and Hepatology, Stanford University, Stanford, CA, USA alHepatology Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas, CEMIC, Ciudad Autónoma de Buenos Aires, Argentina amHepatology Division, Department of Upper GI Diseases, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden |
| dc.format.extent.es.fl_str_mv | 6 p. |
| dc.format.mimetype.es.fl_str_mv | application/pdf |
| dc.identifier.citation.es.fl_str_mv | Efe C, Taşçılar K, Gerussi A y otros. SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis. Journal of Autoimmunity [en línea]. 2022;132. 6 p. |
| dc.identifier.doi.none.fl_str_mv | 10.1016/j.jaut.2022.102906 |
| dc.identifier.eissn.none.fl_str_mv | 0896-8411 |
| dc.identifier.uri.none.fl_str_mv | https://hdl.handle.net/20.500.12008/54650 |
| dc.language.iso.none.fl_str_mv | en eng |
| dc.publisher.es.fl_str_mv | Elsevier |
| dc.relation.none.fl_str_mv | Journal of Autoimmunity. 2022;132 |
| dc.rights.license.none.fl_str_mv | Licencia Creative Commons Atribución (CC - By 4.0) |
| dc.rights.none.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.source.none.fl_str_mv | reponame:COLIBRI instname:Universidad de la República instacron:Universidad de la República |
| dc.subject.es.fl_str_mv | Autoimmunity Breakthrough infection Immunosuppression Liver failure Vaccine |
| dc.subject.other.es.fl_str_mv | COVID-19 VACUNAS CONTRA LA COVID-19 AUTOINMUNIDAD RIESGO A LA SALUD ADULTOS ADOLESCENTE PERSONA DE MEDIANA EDAD ANCIANO HEPATITIS AUTOINMUNE VACUNA BNT162 PRUEBA DE COVID-19 PREVENCIÓN DE ENFERMEDADES HUMANOS ESTUDIOS RETROSPECTIVOS SARS-CoV-2 EPIDEMIOLOGÍA VACUNACIÓN |
| dc.title.none.fl_str_mv | SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis |
| dc.type.es.fl_str_mv | Artículo |
| dc.type.none.fl_str_mv | info:eu-repo/semantics/article |
| dc.type.version.none.fl_str_mv | info:eu-repo/semantics/publishedVersion |
| description | Cumali Efe a,∗,1, Koray Taşçılar b,1, Alessio Gerussi c,d, Francesca Bolis c, Craig Lammert e, Berat Ebik f, Albert Friedrich Stättermayer g, Mustafa Cengiz h, Dilara Turan Gökçe i, Laura Cristoferi c,d, Mirta Peralta j,k, Hatef Massoumi l, Pedro Montes m, Eira Cerda n, Cristina Rigamonti o,p, Suna Yapalı q, Gupse Adali r, Ali Rıza Çalışkan s, Yasemin Balaban t, Fatih Eren u, Tuğçe Eşkazan v, Sezgin Barutçu w, Ellina Lytvyak x, Godolfino Miranda Zazueta y, Meral Akdogan Kayhan h, Alexandra Heurgue-Berlot z, Eleonora De Martin aa, Ahmet Yavuz ab, Murat Bıyık ab, Graciela Castro Narro y, Serkan Duman ac, Nelia Hernandez ad, Nikolaos K Gatselis ae,af, Jonathan Aguirre ag, Ramazan Idilman ac, Marcelo Silva k,ah, Manuel Mendizabal k,ah, Kadri Atay ai, Fatih Güzelbulut aj, Renumathy Dhanasekaran ak, Aldo J Montano-Loza x, George N Dalekos ae,af,2, Ezequiel Ridruejo k,ah,al,2, Pietro Invernizzi c,d,2, Staffan Wahlin am,2 |
| eu_rights_str_mv | openAccess |
| format | article |
| id | COLIBRI_7a288b6cddf1c8186299a8d6f49764b7 |
| identifier_str_mv | Efe C, Taşçılar K, Gerussi A y otros. SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis. Journal of Autoimmunity [en línea]. 2022;132. 6 p. 10.1016/j.jaut.2022.102906 0896-8411 |
| instacron_str | Universidad de la República |
| institution | Universidad de la República |
| instname_str | Universidad de la República |
| language | eng |
| language_invalid_str_mv | en |
| network_acronym_str | COLIBRI |
| network_name_str | COLIBRI |
| oai_identifier_str | oai:colibri.udelar.edu.uy:20.500.12008/54650 |
| publishDate | 2022 |
| reponame_str | COLIBRI |
| repository.mail.fl_str_mv | karina.camps@seciu.edu.uy |
| repository.name.fl_str_mv | COLIBRI - Universidad de la República |
| repository_id_str | 4771 |
| rights_invalid_str_mv | Licencia Creative Commons Atribución (CC - By 4.0) |
| spelling | Efe Cumali, Harran University Hospital (Turquía). Department of GastroenterologyTaşçılar Koray, Friedrich-Alexander University of Erlangen–Nuremberg (Alemania). Department of Medicine 3-Rheumatology and ImmunologyGerussi Alessio, San Gerardo Hospital (Italia). European Reference Network on Hepatological DiseasesBolis Francesca, Università degli Studi di Milano-Bicocca (Italia). Department of Medicine and Surgery. Division of Gastroenterology and Center for Autoimmune Liver DiseasesLammert Craig, Indiana University School of Medicine (E.E.U.U.). Department of MedicineEbik Berat, Gazi Yaşargil Education and Research Hospital (Turquía). Department of GastroenterologyStättermayer Albert F., Medical University of Vienna (Austria). Department of Internal Medicine III, Division of Gastroenterology and HepatologyCengiz Mustafa, Gülhane Training and Research Hospital (Turquía). Department of GastroenterologyGökçe Dilara Turan, Ankara City Hospital (Turquía). Department of GastroenterologyHernández Nelia, Universidad de la República (Uruguay). Facultad de Medicina. Unidad de Gastroenterología y Hepatología2026-04-28T17:28:34Z2026-04-28T17:28:34Z2022Efe C, Taşçılar K, Gerussi A y otros. SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis. Journal of Autoimmunity [en línea]. 2022;132. 6 p.https://hdl.handle.net/20.500.12008/5465010.1016/j.jaut.2022.1029060896-8411Cumali Efe a,∗,1, Koray Taşçılar b,1, Alessio Gerussi c,d, Francesca Bolis c, Craig Lammert e, Berat Ebik f, Albert Friedrich Stättermayer g, Mustafa Cengiz h, Dilara Turan Gökçe i, Laura Cristoferi c,d, Mirta Peralta j,k, Hatef Massoumi l, Pedro Montes m, Eira Cerda n, Cristina Rigamonti o,p, Suna Yapalı q, Gupse Adali r, Ali Rıza Çalışkan s, Yasemin Balaban t, Fatih Eren u, Tuğçe Eşkazan v, Sezgin Barutçu w, Ellina Lytvyak x, Godolfino Miranda Zazueta y, Meral Akdogan Kayhan h, Alexandra Heurgue-Berlot z, Eleonora De Martin aa, Ahmet Yavuz ab, Murat Bıyık ab, Graciela Castro Narro y, Serkan Duman ac, Nelia Hernandez ad, Nikolaos K Gatselis ae,af, Jonathan Aguirre ag, Ramazan Idilman ac, Marcelo Silva k,ah, Manuel Mendizabal k,ah, Kadri Atay ai, Fatih Güzelbulut aj, Renumathy Dhanasekaran ak, Aldo J Montano-Loza x, George N Dalekos ae,af,2, Ezequiel Ridruejo k,ah,al,2, Pietro Invernizzi c,d,2, Staffan Wahlin am,2aDepartment of Gastroenterology, Harran University Hospital, Şanlıurfa, Turkey bDepartment of Medicine 3-Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany cDivision of Gastroenterology and Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy dEuropean Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital, Monza, Italy eDepartment of Medicine Indiana, University School of Medicine, Indianapolis, IN, USA fDepartment of Gastroenterology, Gazi Yaşargil Education and Research Hospital, Diyarbakir, Turkey gDivision of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria hDepartment of Gastroenterology, Gülhane Training and Research Hospital, Ankara, Turkey iDepartment of Gastroenterology, Ankara City Hospital, Ankara, Turkey jHepatology Section, Hospital Francisco J Muñiz, Ciudad Autónoma de Buenos Aires, Argentina kLatin American Liver Research Educational and Awareness Network (LALREAN), Pilar, Argentina lDepartment of Medicine, Montefiore Medical Center, Bronx, NY, USA mGastroenterology and Hepatology Unit, Hospital Nacional Daniel A. Carrión, Callao, Peru nHepatology Unit, Hospital Militar Central de México, Ciudad de México, Mexico oDepartment of Translational Medicine, Università del Piemonte Orientale UPO, Novara, Italy pDivision of Internal Medicine, “AOU Maggiore della Carità”, Novara, Italy qDepartment of Gastroenterology, Acıbadem University School of Medicine, İstanbul, Turkey rDepartment of Gastroenterology, Umraniye Education and Research Hospital, Istanbul, Turkey sDepartment of Gastroenterology, Adıyaman University, Adıyaman, Turkey tDepartment of Gastroenterology, Faculty of Medicine, Hacettepe University, Ankara, Turkey uDepartment of Gastroenterology, Medical Faculty, Uludag University, Bursa, Turkey vDepartment of Gastroenterology, Cerrahpaşa School of Medicine, İstanbul, Turkey wDepartment of Gastroenterology, University of Gaziantep Medical Faculty, Gaziantep, Turkey xUniversity of Alberta Division of Gastroenterology and Liver Unit, Edmonton, AB, Canada yGastroenterology Unit, Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, Ciudad de México, Mexico zDepartment of Hepato-Gastroenterology, CHU Reims, Reims, France aaCentre Hepato-Biliaire, Hôpital Paul-Brousse, FHU Hepatinov, INSERM Unit UMR 1193, Univ Paris-Saclay, France abDivision of Gastroenterology, Necmettin Erbakan University, Meram School of Medicine, Konya, Turkey acDepartment of Gastroenterology, Ankara University Medical Faculty, Ankara, Turkey adGastroenterology and Hepatology Unit, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay aeDepartment of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, Greece afEuropean Reference Network on Hepatological Diseases (ERN RARE-LIVER), General University Hospital of Larissa, Larissa, Greece agHepatology Unit, Hospital Ángeles Pedregal, Ciudad de México, Mexico ahHepatology and Liver Transplant Unit, Hospital Universitario Austral, Pilar, Argentina aiDepartment of Gastroenterology, Mardin State Hospital, Mardin, Turkey ajDepartment of Gastroenterology, Haydarpaşa Numune Education and Research Hospital, İstanbul, Turkey akDivision of Gastroenterology and Hepatology, Stanford University, Stanford, CA, USA alHepatology Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas, CEMIC, Ciudad Autónoma de Buenos Aires, Argentina amHepatology Division, Department of Upper GI Diseases, Karolinska Institutet and Karolinska University Hospital, Stockholm, SwedenBackground: Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer- BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine. Patients and methods: We performed a retrospective study on AIH patients with COVID-19. The outcomes of AIH patients who had acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection after at least one dose of COVID-19 vaccine were compared to unvaccinated patients with AIH. COVID-19 outcome was classified according to clinical state during the disease course as: (i) no hospitalization, (ii) hospitalization without oxygen supplementation, (iii) hospitalization with oxygen supplementation by nasal cannula or mask, (iv) intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v) ICU admission with invasive mechanical ventilation or (vi) death, and data was analyzed using ordinal logistic regression. Results: We included 413 (258 unvaccinated and 155 vaccinated) patients (81%, female) with a median age of 52 (range: 17-85) years at COVID-19 diagnosis. The rates of hospitalization were (36.4% vs. 14.2%), need for any supplemental oxygen (29.5% vs. 9%) and mortality (7% vs. 0.6%) in unvaccinated and vaccinated AIH patients with COVID-19. Having received at least one dose of SARS-CoV-2 vaccine was associated with a significantly lower risk of worse COVID-19 severity, after adjusting for age, sex, comorbidities and presence of cirrhosis (adjusted odds ratio [aOR] 0.18, 95% confidence interval [CI], 0.10-0.31). Overall, vaccination against SARS-CoV-2 was associated with a significantly lower risk of mortality from COVID-19 (aOR 0.20, 95% CI 0.11-0.35). Conclusions: SARS-CoV-2 vaccination significantly reduced the risk of COVID-19 severity and mortality in patients with AIH.Submitted by Almiñana María Cecilia (marialminana@gmail.com) on 2026-04-27T17:20:36Z No. of bitstreams: 2 license_rdf: 25630 bytes, checksum: e7132498e7c1fe99f7096667baa99b25 (MD5) SARS CoV2 vaccination and risk of severe COVID19 outcomes.pdf: 634814 bytes, checksum: 7423378789254038f4f1a94094dff740 (MD5)Approved for entry into archive by Almiñana María Cecilia (marialminana@gmail.com) on 2026-04-27T18:14:35Z (GMT) No. of bitstreams: 2 license_rdf: 25630 bytes, checksum: e7132498e7c1fe99f7096667baa99b25 (MD5) SARS CoV2 vaccination and risk of severe COVID19 outcomes.pdf: 634814 bytes, checksum: 7423378789254038f4f1a94094dff740 (MD5)Made available in DSpace by Camps Karina (karina.camps@seciu.edu.uy) on 2026-04-28T17:28:34Z (GMT). No. of bitstreams: 2 license_rdf: 25630 bytes, checksum: e7132498e7c1fe99f7096667baa99b25 (MD5) SARS CoV2 vaccination and risk of severe COVID19 outcomes.pdf: 634814 bytes, checksum: 7423378789254038f4f1a94094dff740 (MD5) Previous issue date: 20226 p.application/pdfenengElsevierJournal of Autoimmunity. 2022;132Las obras depositadas en el Repositorio se rigen por la Ordenanza de los Derechos de la Propiedad Intelectual de la Universidad de la República.(Res. Nº 91 de C.D.C. de 8/III/1994 – D.O. 7/IV/1994) y por la Ordenanza del Repositorio Abierto de la Universidad de la República (Res. Nº 16 de C.D.C. de 07/10/2014)info:eu-repo/semantics/openAccessLicencia Creative Commons Atribución (CC - By 4.0)AutoimmunityBreakthrough infectionImmunosuppressionLiver failureVaccineCOVID-19VACUNAS CONTRA LA COVID-19AUTOINMUNIDADRIESGO A LA SALUDADULTOSADOLESCENTEPERSONA DE MEDIANA EDADANCIANOHEPATITIS AUTOINMUNEVACUNA BNT162PRUEBA DE COVID-19PREVENCIÓN DE ENFERMEDADESHUMANOSESTUDIOS RETROSPECTIVOSSARS-CoV-2EPIDEMIOLOGÍAVACUNACIÓNSARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitisArtículoinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionreponame:COLIBRIinstname:Universidad de la Repúblicainstacron:Universidad de la RepúblicaEfe, CumaliTaşçılar, KorayGerussi, AlessioBolis, FrancescaLammert, CraigEbik, BeratStättermayer, Albert F.Cengiz, MustafaGökçe, Dilara TuranHernández, NeliaLICENSElicense.txtlicense.txttext/plain; charset=utf-84267http://localhost:8080/xmlui/bitstream/20.500.12008/54650/5/license.txt6429389a7df7277b72b7924fdc7d47a9MD55CC-LICENSElicense_urllicense_urltext/plain; charset=utf-844http://localhost:8080/xmlui/bitstream/20.500.12008/54650/2/license_urla0ebbeafb9d2ec7cbb19d7137ebc392cMD52license_textlicense_texttext/html; charset=utf-831363http://localhost:8080/xmlui/bitstream/20.500.12008/54650/3/license_text0e79e635ad5d883764003e78793ad1deMD53license_rdflicense_rdfapplication/rdf+xml; charset=utf-825630http://localhost:8080/xmlui/bitstream/20.500.12008/54650/4/license_rdfe7132498e7c1fe99f7096667baa99b25MD54ORIGINALSARS CoV2 vaccination and risk of severe COVID19 outcomes.pdfSARS CoV2 vaccination and risk of severe COVID19 outcomes.pdfapplication/pdf634814http://localhost:8080/xmlui/bitstream/20.500.12008/54650/1/SARS+CoV2+vaccination+and+risk+of+severe+COVID19+outcomes.pdf7423378789254038f4f1a94094dff740MD5120.500.12008/546502026-04-28 14:28:34.232oai:colibri.udelar.edu.uy:20.500.12008/54650VGVybWlub3MgeSBjb25kaWNpb25lcyByZWxhdGl2YXMgYWwgZGVwb3NpdG8gZGUgb2JyYXMKCgpMYXMgb2JyYXMgZGVwb3NpdGFkYXMgZW4gZWwgUmVwb3NpdG9yaW8gc2UgcmlnZW4gcG9yIGxhIE9yZGVuYW56YSBkZSBsb3MgRGVyZWNob3MgZGUgbGEgUHJvcGllZGFkIEludGVsZWN0dWFsICBkZSBsYSBVbml2ZXJzaWRhZCBEZSBMYSBSZXDDumJsaWNhLiAoUmVzLiBOwrogOTEgZGUgQy5ELkMuIGRlIDgvSUlJLzE5OTQg4oCTIEQuTy4gNy9JVi8xOTk0KSB5ICBwb3IgbGEgT3JkZW5hbnphIGRlbCBSZXBvc2l0b3JpbyBBYmllcnRvIGRlIGxhIFVuaXZlcnNpZGFkIGRlIGxhIFJlcMO6YmxpY2EgKFJlcy4gTsK6IDE2IGRlIEMuRC5DLiBkZSAwNy8xMC8yMDE0KS4gCgpBY2VwdGFuZG8gZWwgYXV0b3IgZXN0b3MgdMOpcm1pbm9zIHkgY29uZGljaW9uZXMgZGUgZGVww7NzaXRvIGVuIENPTElCUkksIGxhIFVuaXZlcnNpZGFkIGRlIFJlcMO6YmxpY2EgcHJvY2VkZXLDoSBhOiAgCgphKSBhcmNoaXZhciBtw6FzIGRlIHVuYSBjb3BpYSBkZSBsYSBvYnJhIGVuIGxvcyBzZXJ2aWRvcmVzIGRlIGxhIFVuaXZlcnNpZGFkIGEgbG9zIGVmZWN0b3MgZGUgZ2FyYW50aXphciBhY2Nlc28sIHNlZ3VyaWRhZCB5IHByZXNlcnZhY2nDs24KYikgY29udmVydGlyIGxhIG9icmEgYSBvdHJvcyBmb3JtYXRvcyBzaSBmdWVyYSBuZWNlc2FyaW8gIHBhcmEgZmFjaWxpdGFyIHN1IHByZXNlcnZhY2nDs24geSBhY2Nlc2liaWxpZGFkIHNpbiBhbHRlcmFyIHN1IGNvbnRlbmlkby4KYykgcmVhbGl6YXIgbGEgY29tdW5pY2FjacOzbiBww7pibGljYSB5IGRpc3BvbmVyIGVsIGFjY2VzbyBsaWJyZSB5IGdyYXR1aXRvIGEgdHJhdsOpcyBkZSBJbnRlcm5ldCBtZWRpYW50ZSBsYSBwdWJsaWNhY2nDs24gZGUgbGEgb2JyYSBiYWpvIGxhIGxpY2VuY2lhIENyZWF0aXZlIENvbW1vbnMgc2VsZWNjaW9uYWRhIHBvciBlbCBwcm9waW8gYXV0b3IuCgoKRW4gY2FzbyBxdWUgZWwgYXV0b3IgaGF5YSBkaWZ1bmRpZG8geSBkYWRvIGEgcHVibGljaWRhZCBhIGxhIG9icmEgZW4gZm9ybWEgcHJldmlhLCAgcG9kcsOhIHNvbGljaXRhciB1biBwZXLDrW9kbyBkZSBlbWJhcmdvIHNvYnJlIGxhIGRpc3BvbmliaWxpZGFkIHDDumJsaWNhIGRlIGxhIG1pc21hLCBlbCBjdWFsIGNvbWVuemFyw6EgYSBwYXJ0aXIgZGUgbGEgYWNlcHRhY2nDs24gZGUgZXN0ZSBkb2N1bWVudG8geSBoYXN0YSBsYSBmZWNoYSBxdWUgaW5kaXF1ZSAuCgpFbCBhdXRvciBhc2VndXJhIHF1ZSBsYSBvYnJhIG5vIGluZnJpZ2UgbmluZ8O6biBkZXJlY2hvIHNvYnJlIHRlcmNlcm9zLCB5YSBzZWEgZGUgcHJvcGllZGFkIGludGVsZWN0dWFsIG8gY3VhbHF1aWVyIG90cm8uCgpFbCBhdXRvciBnYXJhbnRpemEgcXVlIHNpIGVsIGRvY3VtZW50byBjb250aWVuZSBtYXRlcmlhbGVzIGRlIGxvcyBjdWFsZXMgbm8gdGllbmUgbG9zIGRlcmVjaG9zIGRlIGF1dG9yLCAgaGEgb2J0ZW5pZG8gZWwgcGVybWlzbyBkZWwgcHJvcGlldGFyaW8gZGUgbG9zIGRlcmVjaG9zIGRlIGF1dG9yLCB5IHF1ZSBlc2UgbWF0ZXJpYWwgY3V5b3MgZGVyZWNob3Mgc29uIGRlIHRlcmNlcm9zIGVzdMOhIGNsYXJhbWVudGUgaWRlbnRpZmljYWRvIHkgcmVjb25vY2lkbyBlbiBlbCB0ZXh0byBvIGNvbnRlbmlkbyBkZWwgZG9jdW1lbnRvIGRlcG9zaXRhZG8gZW4gZWwgUmVwb3NpdG9yaW8uCgpFbiBvYnJhcyBkZSBhdXRvcsOtYSBtw7psdGlwbGUgL3NlIHByZXN1bWUvIHF1ZSBlbCBhdXRvciBkZXBvc2l0YW50ZSBkZWNsYXJhIHF1ZSBoYSByZWNhYmFkbyBlbCBjb25zZW50aW1pZW50byBkZSB0b2RvcyBsb3MgYXV0b3JlcyBwYXJhIHB1YmxpY2FybGEgZW4gZWwgUmVwb3NpdG9yaW8sIHNpZW5kbyDDqXN0ZSBlbCDDum5pY28gcmVzcG9uc2FibGUgZnJlbnRlIGEgY3VhbHF1aWVyIHRpcG8gZGUgcmVjbGFtYWNpw7NuIGRlIGxvcyBvdHJvcyBjb2F1dG9yZXMuCgpFbCBhdXRvciBzZXLDoSByZXNwb25zYWJsZSBkZWwgY29udGVuaWRvIGRlIGxvcyBkb2N1bWVudG9zIHF1ZSBkZXBvc2l0YS4gTGEgVURFTEFSIG5vIHNlcsOhIHJlc3BvbnNhYmxlIHBvciBsYXMgZXZlbnR1YWxlcyB2aW9sYWNpb25lcyBhbCBkZXJlY2hvIGRlIHByb3BpZWRhZCBpbnRlbGVjdHVhbCBlbiBxdWUgcHVlZGEgaW5jdXJyaXIgZWwgYXV0b3IuCgpBbnRlIGN1YWxxdWllciBkZW51bmNpYSBkZSB2aW9sYWNpw7NuIGRlIGRlcmVjaG9zIGRlIHByb3BpZWRhZCBpbnRlbGVjdHVhbCwgbGEgVURFTEFSICBhZG9wdGFyw6EgdG9kYXMgbGFzIG1lZGlkYXMgbmVjZXNhcmlhcyBwYXJhIGV2aXRhciBsYSBjb250aW51YWNpw7NuIGRlIGRpY2hhIGluZnJhY2Npw7NuLCBsYXMgcXVlIHBvZHLDoW4gaW5jbHVpciBlbCByZXRpcm8gZGVsIGFjY2VzbyBhIGxvcyBjb250ZW5pZG9zIHkvbyBtZXRhZGF0b3MgZGVsIGRvY3VtZW50byByZXNwZWN0aXZvLgoKTGEgb2JyYSBzZSBwb25kcsOhIGEgZGlzcG9zaWNpw7NuIGRlbCBww7pibGljbyBhIHRyYXbDqXMgZGUgbGFzIGxpY2VuY2lhcyBDcmVhdGl2ZSBDb21tb25zLCBlbCBhdXRvciBwb2Ryw6Egc2VsZWNjaW9uYXIgdW5hIGRlIGxhcyA2IGxpY2VuY2lhcyBkaXNwb25pYmxlczoKCgpBdHJpYnVjacOzbiAoQ0MgLSBCeSk6IFBlcm1pdGUgdXNhciBsYSBvYnJhIHkgZ2VuZXJhciBvYnJhcyBkZXJpdmFkYXMsIGluY2x1c28gY29uIGZpbmVzIGNvbWVyY2lhbGVzLCBzaWVtcHJlIHF1ZSBzZSByZWNvbm96Y2EgYWwgYXV0b3IuCgpBdHJpYnVjacOzbiDigJMgQ29tcGFydGlyIElndWFsIChDQyAtIEJ5LVNBKTogUGVybWl0ZSB1c2FyIGxhIG9icmEgeSBnZW5lcmFyIG9icmFzIGRlcml2YWRhcywgaW5jbHVzbyBjb24gZmluZXMgY29tZXJjaWFsZXMsIHBlcm8gbGEgZGlzdHJpYnVjacOzbiBkZSBsYXMgb2JyYXMgZGVyaXZhZGFzIGRlYmUgaGFjZXJzZSBtZWRpYW50ZSB1bmEgbGljZW5jaWEgaWTDqW50aWNhIGEgbGEgZGUgbGEgb2JyYSBvcmlnaW5hbCwgcmVjb25vY2llbmRvIGEgbG9zIGF1dG9yZXMuCgpBdHJpYnVjacOzbiDigJMgTm8gQ29tZXJjaWFsIChDQyAtIEJ5LU5DKTogUGVybWl0ZSB1c2FyIGxhIG9icmEgeSBnZW5lcmFyIG9icmFzIGRlcml2YWRhcywgc2llbXByZSB5IGN1YW5kbyBlc29zIHVzb3Mgbm8gdGVuZ2FuIGZpbmVzIGNvbWVyY2lhbGVzLCByZWNvbm9jaWVuZG8gYWwgYXV0b3IuCgpBdHJpYnVjacOzbiDigJMgU2luIERlcml2YWRhcyAoQ0MgLSBCeS1ORCk6IFBlcm1pdGUgZWwgdXNvIGRlIGxhIG9icmEsIGluY2x1c28gY29uIGZpbmVzIGNvbWVyY2lhbGVzLCBwZXJvIG5vIHNlIHBlcm1pdGUgZ2VuZXJhciBvYnJhcyBkZXJpdmFkYXMsIGRlYmllbmRvIHJlY29ub2NlciBhbCBhdXRvci4KCkF0cmlidWNpw7NuIOKAkyBObyBDb21lcmNpYWwg4oCTIENvbXBhcnRpciBJZ3VhbCAoQ0Mg4oCTIEJ5LU5DLVNBKTogUGVybWl0ZSB1c2FyIGxhIG9icmEgeSBnZW5lcmFyIG9icmFzIGRlcml2YWRhcywgc2llbXByZSB5IGN1YW5kbyBlc29zIHVzb3Mgbm8gdGVuZ2FuIGZpbmVzIGNvbWVyY2lhbGVzIHkgbGEgZGlzdHJpYnVjacOzbiBkZSBsYXMgb2JyYXMgZGVyaXZhZGFzIHNlIGhhZ2EgbWVkaWFudGUgbGljZW5jaWEgaWTDqW50aWNhIGEgbGEgZGUgbGEgb2JyYSBvcmlnaW5hbCwgcmVjb25vY2llbmRvIGEgbG9zIGF1dG9yZXMuCgpBdHJpYnVjacOzbiDigJMgTm8gQ29tZXJjaWFsIOKAkyBTaW4gRGVyaXZhZGFzIChDQyAtIEJ5LU5DLU5EKTogUGVybWl0ZSB1c2FyIGxhIG9icmEsIHBlcm8gbm8gc2UgcGVybWl0ZSBnZW5lcmFyIG9icmFzIGRlcml2YWRhcyB5IG5vIHNlIHBlcm1pdGUgdXNvIGNvbiBmaW5lcyBjb21lcmNpYWxlcywgZGViaWVuZG8gcmVjb25vY2VyIGFsIGF1dG9yLgoKTG9zIHVzb3MgcHJldmlzdG9zIGVuIGxhcyBsaWNlbmNpYXMgaW5jbHV5ZW4gbGEgZW5hamVuYWNpw7NuLCByZXByb2R1Y2Npw7NuLCBjb211bmljYWNpw7NuLCBwdWJsaWNhY2nDs24sIGRpc3RyaWJ1Y2nDs24geSBwdWVzdGEgYSBkaXNwb3NpY2nDs24gZGVsIHDDumJsaWNvLiBMYSBjcmVhY2nDs24gZGUgb2JyYXMgZGVyaXZhZGFzIGluY2x1eWUgbGEgYWRhcHRhY2nDs24sIHRyYWR1Y2Npw7NuIHkgZWwgcmVtaXguCgpDdWFuZG8gc2Ugc2VsZWNjaW9uZSB1bmEgbGljZW5jaWEgcXVlIGhhYmlsaXRlIHVzb3MgY29tZXJjaWFsZXMsIGVsIGRlcMOzc2l0byBkZWJlcsOhIHNlciBhY29tcGHDsWFkbyBkZWwgYXZhbCBkZWwgamVyYXJjYSBtw6F4aW1vIGRlbCBTZXJ2aWNpbyBjb3JyZXNwb25kaWVudGUuCg==Institucionalhttps://www.colibri.udelar.edu.uyUniversidad públicahttps://udelar.edu.uy/https://www.colibri.udelar.edu.uy/oai/requestkarina.camps@seciu.edu.uyUruguayopendoar:47712026-04-28T17:28:34COLIBRI - Universidad de la Repúblicafalse |
| spellingShingle | SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis Efe, Cumali Autoimmunity Breakthrough infection Immunosuppression Liver failure Vaccine COVID-19 VACUNAS CONTRA LA COVID-19 AUTOINMUNIDAD RIESGO A LA SALUD ADULTOS ADOLESCENTE PERSONA DE MEDIANA EDAD ANCIANO HEPATITIS AUTOINMUNE VACUNA BNT162 PRUEBA DE COVID-19 PREVENCIÓN DE ENFERMEDADES HUMANOS ESTUDIOS RETROSPECTIVOS SARS-CoV-2 EPIDEMIOLOGÍA VACUNACIÓN |
| status_str | publishedVersion |
| title | SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis |
| title_full | SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis |
| title_fullStr | SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis |
| title_full_unstemmed | SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis |
| title_short | SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis |
| title_sort | SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis |
| topic | Autoimmunity Breakthrough infection Immunosuppression Liver failure Vaccine COVID-19 VACUNAS CONTRA LA COVID-19 AUTOINMUNIDAD RIESGO A LA SALUD ADULTOS ADOLESCENTE PERSONA DE MEDIANA EDAD ANCIANO HEPATITIS AUTOINMUNE VACUNA BNT162 PRUEBA DE COVID-19 PREVENCIÓN DE ENFERMEDADES HUMANOS ESTUDIOS RETROSPECTIVOS SARS-CoV-2 EPIDEMIOLOGÍA VACUNACIÓN |
| url | https://hdl.handle.net/20.500.12008/54650 |
